Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Nevis Brands Inc C.NEVI

Alternate Symbol(s):  PSCBF

Nevis Brands Inc., formerly Pascal Biosciences Inc., provides cannabis brands throughout the United States. The Company provides products in Washington, Oregon, California, Ohio, Arizona and Colorado through partners and licensees. Its products include Major, which is a cannabis beverage. Major is a high-dose tetrahydrocannabinol (THC) beverage that delivers a consistent cannabis experience with no cannabis taste or smell. Major offers various flavors, such as volcanic orange mango, sunset pink lemonade, pacific coast blue raspberry, dreamin' of passion, and sacred grape. It also offers Major Minis, which is a smaller 2 ounce (oz) shot. Major Minis comes in three flavors, such as blueberry, fruit punch, and blackberry lemonade.


CSE:NEVI - Post by User

Post by newdaydawningon Jul 10, 2020 7:24pm
145 Views
Post# 31254200

Why Pascal is soaring

Why Pascal is soaringPascal determined that certain cannabinoids increase expression of the Major Histocompatibility Complex, which is critical for providing a strong immune response to cancer cells. This same activity could be beneficial for cells infected with the novel coronavirus, because the immune system will better recognize viral infected cells. We are in the process of testing our cannabinoids in a COVID-19 direct viral assay, which may lead to animal studies. In addition, Pascal will be testing PAS-403, our lead compound for glioblastoma, in a COVID-19 direct viral assay. PAS-403 is a mitotic inhibitor with the same mechanism of action as colchicine, which is currently being tested in human clinical trials as a potential treatment for COVID-19.

https://www.pascalbiosciences.com/pascal-biosciences-announces-continuing-discussions-with-sorse-technology-and-testing-of-cannabinoids-for-covid-19-treatment/
<< Previous
Bullboard Posts
Next >>